Trial Profile
Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Dec 2014
Price :
$35
*
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Amyloid polyneuropathy; Cardiomyopathies
- Focus Pharmacokinetics
- Sponsors Pfizer
- 12 Dec 2014 New trial record